SFM
ZNTL icon

Sphera Funds Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sphera Funds Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-175,140
Closed -$7.6M – 171
2021
Q1 		$7.6M Sell
175,140
-15,656
-8% -$674K 0.58% 46
2020
Q4 		$9.91M Sell
190,796
-4,200
-2% -$189K 0.88% 32
2020
Q3 		$6.37M Buy
+194,996
New +$6.83M 0.63% 46

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's ZNTL Position: Q2 2021 in Review

Sphera Funds Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2021, closing a stake of 175,140 shares — an estimated $7.6M sold.

Sphera Funds Management first reported a position in ZNTL in Q3 2020 and held it in 3 quarters. The position peaked at $9.91M in Q4 2020. 120 funds tracked by Wall St. Rank hold ZNTL as of Q2 2021.

  • Sphera Funds Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Sphera Funds Management sold 175,140 Zentalis Pharmaceuticals shares in Q2 2021, an estimated $7.6M.
  • Sphera Funds Management first reported a position in Zentalis Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Sphera Funds Management's Zentalis Pharmaceuticals position peaked at $9.91M in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2021.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.